Objectives: To compare the efficacy and safety of thymoglobulin compared with basiliximab in patients who had kidney transplants and are at high risk for acute rejection and delayed graft function. Materials and Methods: A retrospective review of patients who had 1 or more risk factors for acute rejection and delayed graft function and who were given either thymoglobulin or basiliximab for induction therapy. Incidences of acute rejection, antibody-treated acute rejection, delayed graft function, chronic rejection, cancer, infection, leucopenia, and thrombocytopenia were compared between thymoglobulin and basiliximab groups. Serum creatinine levels within 1 year and long-term graft and patient survival also were compared. Results: A total of 327 patients were included. Incidences of acute rejection, antibody-treated acute rejection, delayed graft function, and chronic rejection were significantly lower in the thymoglobulin group than in the basiliximab group (P < .05). Serum creatinine levels were lower in the thymoglobulin group on postoperative days 7, 14, and 30 (P < .05). There were no statistically significant differences regarding long-term graft and patient survival, cancer, or total infection rate between the groups. Incidences of Cytomegalovirus infection, leucopenia, and thrombocytopenia were significantly higher in the thymoglobulin group (P < .05).
Introduction
In patients with kidney transplants, acute rejection has been shown to significantly reduce long-term graft survival. 1 Delayed graft function (DGF) may increase the incidence of acute rejection and have negative effects on long-term graft and patient survival. 2, 3 Some risk factors have been reported to be related to acute rejection and DGF after kidney transplant, such as higher donor age, long cold ischemia time, repeat transplant, positive panel-reactive antibody test results, and mismatched histocompatibility leukocyte antigen (HLA). [4] [5] [6] Induction therapy has been widely used to reduce acute rejection and DGF after kidney transplants. Thymoglobulin and basiliximab are the most commonly prescribed medications in induction therapy. Several studies have shown that both thymoglobulin and basiliximab could significantly decrease the incidence of acute rejection and DGF after a kidney transplant. [7] [8] [9] However, whether these drugs have similar efficacy and safety in patients who are at high risk for acute rejection and DGF remains to be determined.
In the present study, we retrospectively reviewed 327 patients who had kidney transplants and 1 or more risk factors for acute rejection and DGF and who were given either thymoglobulin or basiliximab for induction therapy. Drug efficacy and safety were compared between these 2 induction therapy groups.
Materials and Methods
The present study was a retrospective cohort study conducted at The First Affiliated Hospital of Sun Yat-Sen University in South China. The study protocol was approved by the Institutional Review Board of The First Affiliated Hospital of Sun Yat-Sen University. No prisoner organs were used in this study. All protocols conformed with the ethical guidelines of the 1975 Helsinki Declaration.
Inclusion criteria for patients included the following: (1) received deceased-donor kidney transplant at The First Affiliated Hospital of Sun Yat-Sen University between January 1998 and December 2005, (2) aged 18 to 65 years, (3) at least 1 risk factor for acute rejection and DGF as described in Table 1 , and (4) received either thymoglobulin or basiliximab as induction therapy. The exclusion criteria included the following: (1) received multiple organ transplants, (2) received immunosuppressive therapy before kidney transplant, (3) received sirolimus or azathioprine as maintenance therapy, (4) seropositive for hepatitis B surface antigen or antibody against hepatitis C virus, and (5) cancer within 2 years before kidney transplant.
Induction therapy
Patients included in the study were divided into a thymoglobulin group or basiliximab group depending on whether they received thymoglobulin or basiliximab as induction therapy. Patients in the thymoglobulin group received thymoglobulin (1 mg/kg/d intravenously [IV]) during kidney transplant surgery and on days 1 and 2 after surgery. Patients in the basiliximab group received basiliximab (20 mg IV) during kidney transplant surgery and on day 4 after surgery. Methylprednisolone (500 mg/d IV) was administered in both groups during transplant surgery and on postoperative days 1 and 2.
Maintenance immunosuppressive regimen
Patients received mycophenolate mofetil (MMF) 750 mg orally twice daily immediately after kidney transplant, and MMF was tapered to 500 mg twice daily within 1 month and to 250 mg twice daily after 1 year. Tacrolimus and cyclosporine were started on postoperative day 3. The initial dosage of tacrolimus was 0.1 mg/kg daily. The tacrolimus trough level was 5 to 10 ng/mL within the first 6 months and then tapered to 4 to 6 ng/mL within 1 year, and 3 to 5 ng/mL after 1 year. The initial dose of cyclosporine was 5 mg/kg daily. Its trough level was 150 to 250 ng/mL within the first 6 months, then tapered to 130 to 180 ng/mL within 1 year and 120 to 150 ng/mL after 1 year. Prednisone 30 mg daily was stated on postoperative day 3 and tapered to 5 mg daily within 6 months.
Diagnosis and treatment
Acute rejection was diagnosed with such clinical manifestations as fever, oliguria, and serum creatinine elevation, and the diagnosis was confirmed by allograft biopsy. When acute rejection was diagnosed, methylprednisolone (500 mg/d IV) was administered for 3 days. If steroid therapy had no beneficial effect, anti-thymocyte globulin (rabbit) (1 mg/kg/d) or muromonab-CD3 (5 mg/d) was administered for 7 to 10 days.
Prophylaxis
All transplant recipients received intravenous ganciclovir sodium for cytomegalovirus (CMV) prophylaxis from postoperative day 1 to day 14. This administration was followed by maintenance therapy with oral ganciclovir for 90 days. Sulfamethoxazole was given orally for 3 months for Pneumocystis carinii prophylaxis.
Primary endpoints
The primary efficacy endpoints included acute rejection, antibody-treated acute rejection, DGF, chronic rejection, graft loss, and patient death. Longterm graft and patient survival, serum creatinine level within 1 year, infection, cancer, leucopenia, and thrombocytopenia also were analyzed.
Definition
Acute rejection and chronic rejection were confirmed by biopsy. Antibody-treated acute rejection was defined as acute rejection in which anti-thymocyte globulin or muromonab-CD3 steroids, were required for treatment. Delayed graft function was defined as a requirement for dialysis during the first week after kidney transplant.
Statistical analyses All data were analyzed by SPSS statistical software (SPSS: An IBM Company, Windows version 16.0, IBM Corporation, Armonk, New York, USA). Graft and patient survival were calculated by the Kaplan-Meier method, and survival curves were compared using the log-rank test. Categorical variables were compared using the chi-square test or Fisher exact test. Continuous variables were compared using the t test. A value for P < .05 was considered significant.
Results
A total of 327 patients were included in the present study. Among these patients, 149 (45.6%) received thymoglobulin and 178 (54.4%) received basiliximab. The median follow-up was 8.2 years in the thymoglobulin group and 8.5 years in the basiliximab group. Risk factors for acute rejection and DGF in the thymoglobulin and basiliximab groups are compared in Table 1 . Baseline demographic characteristics for patients in the thymoglobulin and basiliximab groups are summarized in Table 2 . The data show that there were no significant differences in risk factors, sex, age, weight, dialysis, or maintenance therapy between the thymoglobulin and basiliximab groups.
The acute rejection rate in the thymoglobulin group was 16.8%, compared with 30.3% in the basiliximab group (P = .004). Antibody-treated acute rejection rate was 5.4% versus 12.4% in the thymoglobulin group versus the basiliximab group (P = .029). These results show that thymoglobulin was significantly more effective than basiliximab in reducing acute rejection, especially antibody-treated acute rejection, after kidney transplant.
Banff criteria suggest that biopsy-proven acute rejection was more severe in the basiliximab group than in the thymoglobulin group (Table 3) , though chisquare test results indicated no statistically significant difference (P = .268). Incidences of DGF and chronic rejection were significantly lower in the thymoglobulin group than in the basiliximab group (26.2% vs 37.1%, 10.7% vs 19.1%; P < .05), as shown in Table 4 . No statistically significant differences were found in long-term graft survival (Figure 1 ) or patient survival (Figure 2 ) between the thymoglobulin and basiliximab groups. The causes of graft loss were similar in both groups, including death with functioning grafts, chronic rejection, acute rejection, and recurrent nephropathy. The causes of patient death also were similar in both groups, with infection, cardiovascular disease, and renal function failure being the most common causes.
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Serum creatinine levels were significantly lower in the thymoglobulin group than in the basiliximab group on postoperative days 7, 14, and 30 (P = .023, .015, and .032) (Figure 3 ). There was no statistically significant difference in total infection rate between the thymoglobulin and basiliximab groups (64.4% vs 64.2%; P > .05), but CMV infection was more common in the thymoglobulin group than in the basiliximab group (28.2% vs 15.7%; P < .05). The incidence of cancer was similar in both groups. The leucopenia and thrombocytopenia rates were significantly higher in the thymoglobulin group than in the basiliximab group (22.8% vs 11.8%, 8.1% vs 2.8%; P < .05) ( Table 5) .
Discussion
In the present retrospective cohort study, we found that thymoglobulin could reduce the incidence of DGF and acute rejection in patients with kidney transplants and who were at high risk for acute rejection and DGF compared with basiliximab. Based on Banff criteria for biopsy-proven acute rejection, the severity of acute rejection was lower in the thymoglobulin group than in the basiliximab group. Thus, it was logical that antibody-treated acute rejection also was significantly decreased in These results demonstrate that thymoglobulin was more effective than basiliximab in controlling the immune response and inflammatory damage to grafts in these high-risk recipients. One prospective study also reported that thymoglobulin could significantly decrease the incidences of acute rejection and antibody-treated rejection compared with basiliximab, but that study found no difference in the incidence of DGF between the 2 drugs. 10 Our results also suggest that thymoglobulin could improve short-term renal function. Within the first month after kidney transplant, the serum creatinine level was much improved in the thymoglobulin group compared to the basiliximab group-perhaps because thymoglobulin reduced the DGF and acute rejection rates in these high-risk transplant recipients. Furthermore, our results show that thymoglobulin could reduce the incidence of chronic rejection. Because many studies have shown that DGF, acute rejection, and chronic rejection are major risk factors for graft loss, [11] [12] [13] thymoglobulin has the potential to improve long-term outcomes in kidney transplant recipients. However, our data show no differences in long-term graft and patient survival between the thymoglobulin and basiliximab groups. Additional prospective studies are needed to compare the long-term efficacy between thymoglobulin and basiliximab.
There was no statistically significant difference in total infection rate between the thymoglobulin and basiliximab groups, but the CMV infection rate was higher in thymoglobulin group. Although routine CMV prophylaxis was used for all recipients after kidney transplant, CMV infection remained common among these recipients. This high infection rate may have been the result of the high dosages of immunosuppressive drugs used in these recipients to counter their risks for DGF and acute rejection. Another factor to consider is that thymoglobulin depleted the T cells, but basiliximab only suppressed the T cells. Thus, it is reasonable that CMV infection would be higher in the thymoglobulin group. Because the incidences of leucopenia and thrombocytopenia also were higher in the thymoglobulin group, it is advisable to pay attention to the white blood cell and platelet counts postoperatively, and to reduce the dose of thymoglobulin if the white blood cell count is lower than 4 × 10 9 /L so as to decrease the infection rate.
Because this is a retrospective cohort study, the patients were not randomized into thymoglobulin and basiliximab groups. We recognize that some selection bias may exist in this study. Additional prospective and randomized studies are warranted to further compare the efficacy of thymoglobulin and basiliximab in high-risk patients receiving kidney transplants.
In conclusion, our study shows that thymoglobulin could significantly reduce the incidences of acute rejection, DGF, and chronic rejection, as well as decrease the severity of acute rejection, in kidney transplant recipients who are at high risk for acute rejection and DGF, compared with basiliximab. Short-term renal function was better in the thymoglobulin group than in the basiliximab group, but long-term outcomes were similar between the groups.
